TREA

79309216 - MEDIGENE IMMUNOTHERAPIES

Follow

Information

  • Trademark
  • 79309216
  • Serial Number
    79309216
  • Registration Number
    6932587
  • Filing Date
    February 23, 2021
    3 years ago
  • Registration Date
    December 27, 2022
    2 years ago
  • Transaction Date
    May 01, 2023
    a year ago
  • Status Date
    December 27, 2022
    2 years ago
  • Published for Opposition Date
    October 11, 2022
    2 years ago
  • Location Date
    December 27, 2022
    2 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    CIANCI, RYAN MICHAEL
  • Attorney Docket Number
    10638-807US1
    Attorney Name
    Lisa C. Pavento
    Law Office Assigned Location Code
    M70
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
MEDIGENE IMMUNOTHERAPIES
Case File Statements
  • GS0051: Medicines for humans and animals, vaccines, serums for medical purposes, and diagnostic preparations for medical purposes for treating cancer, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits for principally comprised of diagnostic preparations for medical purposes that contains at least one of soluble t-cell receptors, and genetically modified cells for determining the type and existence of a tumour in a patient, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; proteins and cells, namely, immune cells carrying a target specific effector protein, protein conjugates, peptides, enzymes and enzyme preparations, in particular antibodies and t-cell proteins, all for medical purposes; t-cells, dendritic cells other immune system cells, and viruses, all for medical purposes;plant extracts for medical purposes; medicines, vaccines, adjuvants, serums all for immunotherapy and the treatment of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits and diagnostic agents comprised of medical diagnostic preparations that contain at least one of soluble t-cell receptors and genetically modified cells for the diagnosis of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods
  • PM0001: MEDI GENE IMMUNOTHERAPY'S
  • GS0441: Medical analysis and medical consulting in connection with the treatment of individuals, in particular in the field of precancerous cells, benign and malignant tumours, autoimmune diseases and immunotherapy
  • D10000: "IMMUNOTHERAPIES"
  • GS0421: Custom molecular biology and biotechnology laboratory services, in particular custom research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic engineering and biotechnological methods to the specifications of others, and in the field of screening for pharmaceutically active components; development of custom test procedures and custom test kits in the field of biotechnology and medicine to the specification of others
Case File Event Statements
  • 5/1/2023 - a year ago
    35 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 4/6/2023 - a year ago
    34 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 4/6/2023 - a year ago
    33 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 3/27/2023 - a year ago
    32 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 12/27/2022 - 2 years ago
    31 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 12/27/2022 - 2 years ago
    30 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 10/17/2022 - 2 years ago
    29 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 10/11/2022 - 2 years ago
    28 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 10/11/2022 - 2 years ago
    27 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/10/2022 - 2 years ago
    26 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 9/28/2022 - 2 years ago
    25 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 9/28/2022 - 2 years ago
    24 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 9/21/2022 - 2 years ago
    23 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 9/21/2022 - 2 years ago
    22 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 9/21/2022 - 2 years ago
    21 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 9/7/2022 - 2 years ago
    20 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/7/2022 - 2 years ago
    19 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 9/7/2022 - 2 years ago
    18 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 9/7/2022 - 2 years ago
    17 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 9/7/2022 - 2 years ago
    16 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 4/14/2022 - 2 years ago
    15 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 4/14/2022 - 2 years ago
    14 - FINAL REFUSAL E-MAILED Type: GNFR
  • 4/14/2022 - 2 years ago
    13 - FINAL REFUSAL WRITTEN Type: CNFR
  • 3/30/2022 - 2 years ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 3/30/2022 - 2 years ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 3/30/2022 - 2 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/30/2021 - 3 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 10/1/2021 - 3 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 10/1/2021 - 3 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 9/27/2021 - 3 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 9/26/2021 - 3 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/17/2021 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/27/2021 - 3 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 4/23/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/22/2021 - 3 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR